Gemma Frisius Fund
Gemma Frisius Fonds NV is venture capital firm set up as a joint venture between the University of Leuven, KBC Private Equity and Fortis Private Equity. Gemma Frisius Fonds NV is dedicated to aid the creation and growth of university-related spin-off companies at the University of Leuven. The firm focuses mainly on first round financing and providing seed, start-up, and early stage capital. However, in order to support a spin-off company's growth during the initial years, it may also provide second round financing. The firm prefers to invest in the Flanders region. It typically seeks to invest between €125,000 ($163,000) and €1 million ($1.31 million) and the investment period usually ranges from 7 to 10 years. Gemma Frisius Fonds NV was founded in 1997 and is based in Leuven, Belgium.
26 past transactions
Aphea.Bio NV/SA
Series B in 2021
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
Virovet
Series B in 2020
ViroVet NV develops virus control solutions for the livestock industry. It offers antiviral drugs for the control and treatment of respiratory diseases of cattle and swine. The company also offers modified live virus vaccines for endemic and epizootic viral livestock diseases. ViroVet NV was founded in 2015 and is based in Leuven, Belgium.
MyCellHub BV
Venture Round in 2022
MyCellHub.com is a pre-startup from the KULeuven in the biotherapeutics industry that aspires to reform the way cell production processes are organised. With a regulatory compliant Saas-platform for data management and analytics, we increase the efficiency of your manufacturing processes, provide actionable insights via cell culture specific process analytics and facilitate regulatory compliance by means of a real-time audit trail and automated batch records.
TROD Medical
Series B in 2013
Trod Medical S.A. operates as a medical equipment and surgical device manufacturer. The company was founded in 2006 and is based in Paris, France.
InOpSys NV
Seed Round in 2015
InOpSys NV specializes in the development and building of flexible, modular and mobile units for onsite toxic wastewater treatment. InOpSys NV is based in Mechelen, Belgium.
UgenTec BVBA
Series A in 2018
UgenTec BVBA delivers an independent diagnostic software platform to help molecular labs with their DNA (PCR) analyses. It offers The FastFinder 2.0 analysis software for helping lab technicians in their analysis of PCR data. It serves biotech companies, labs, and IT companies. The company was founded in 2014 and is based in Hasselt, Belgium.
Elimity
Seed Round in 2019
Elimity helps its customers to protect their important information assets with superior identity governance solutions
Aristo Music Technology
Venture Round in 2008
Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.
Algonomics
Venture Round in 2007
AlgoNomics is a Belgium based biotech company providing structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions. AlgoNomics' premier product is the Epibase® platform for T-cell epitope identification in different population groups, applied in the discovery of vaccines and therapeutic proteins.
Aphea.Bio NV/SA
Series B in 2020
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
Aphea.Bio NV/SA
Series A in 2017
Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.
Rein4ced B.V.B.A.
Seed Round in 2017
Rein4ced B.V.B.A. develops and manufactures impact-resistant and lightweight steel-fiber composite material for bicycle, cars, and aircraft. The company was founded in 2015 and is based in Leuven, Belgium.
Formac Pharmaceuticals
Venture Round in 2007
FORMAC Pharmaceuticals N.V. operates as a pharmaceutical company which delivers drug. It develops delivery forms of generics drugs. Its drug delivery technologies include CMO, an ordered mesoporous silica-based carrier material that enables the release of poorly soluble drug compounds; PVA-co-PEG, a solid dispersion system, which enables the release of poorly soluble drug compounds; magnetic field technology for particle size reduction; and automated manifest system (AMS), a controlled release oral drug delivery system. It also offers biopharmaceutical and physicochemical pre-formulation services for the selection and prioritization of relevant drug candidates prior to formulation. The company was founded in 2007 and is based in Heverlee, Belgium.
reMYND nv
Venture Round in 2018
Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.
They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept.
Porphyrio
Series A in 2014
Porphyrio NV provides poultry and egg production management systems for poultry farming. It offers Lay-Insight, a farm intelligence system for the day-to-day management of egg production; and Broiler-Insight, a farm intelligence system for the day-to-day management of broiler production. The company’s technology provides access control and video surveillance, as well as connects to external ERP systems in poultries. Its technology is available for breeders, broilers, laying hens, and turkeys and other poultry. Porphyrio NV is based in Leuven, Belgium. As of November 7, 2018, Porphyrio NV operates as a subsidiary of Evonik Industries AG.
MyCellHub BV
Seed Round in 2019
MyCellHub.com is a pre-startup from the KULeuven in the biotherapeutics industry that aspires to reform the way cell production processes are organised. With a regulatory compliant Saas-platform for data management and analytics, we increase the efficiency of your manufacturing processes, provide actionable insights via cell culture specific process analytics and facilitate regulatory compliance by means of a real-time audit trail and automated batch records.
Complix
Series B in 2013
Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Augustine Therapeutics N.V.
Seed Round in 2019
Augustine Therapeutics company is a two drug discovery programs to identify new selective HDAC6 inhibitors and GABABR1a agonists for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin repair.
Trendminer
Series B in 2015
Trendminer develops data search and mining software solutions for the process industry. It offers TMsearch that empowers the process specialists to find process trends; TMcapture that creates shift logbooks and adds the ability to manually add visual annotations straight into the trend client; and TMmonitor that allows users to monitor the progress of processes compared to the preferred states. The company was founded in 2013 and is based in Hasselt, Belgium with additional offices in Houston, Texas and Köln, Germany. As of June 12, 2018, TrendMiner NV operates as a subsidiary of Software Aktiengesellschaft.
Cartagenia
Venture Round in 2011
Cartagenia delivers expert systems and services to enable genetic labs and clinicians to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high quality genetic interpretation and counseling.
ArtiQ
Seed Round in 2019
ArtiQ NV develops ArtiQ|PFT, an artificial intelligence-based medical software that helps doctors to diagnose, treat, and monitor respiratory problems. Its software automatically processes pulmonary function test data and generates a clinical report. ArtiQ NV was founded in 2019 and is based in Leuven, Belgium.
Zeopore Technologies
Seed Round in 2018
Zeopore Technologies NV engages in producing mesoporous zeolite for the refining and petrochemical industry. The company was founded in 2017 and is based in Leuven, Belgium.
Cartagenia
Venture Round in 2014
Cartagenia delivers expert systems and services to enable genetic labs and clinicians to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high quality genetic interpretation and counseling.
Trendminer
Series A in 2010
Trendminer develops data search and mining software solutions for the process industry. It offers TMsearch that empowers the process specialists to find process trends; TMcapture that creates shift logbooks and adds the ability to manually add visual annotations straight into the trend client; and TMmonitor that allows users to monitor the progress of processes compared to the preferred states. The company was founded in 2013 and is based in Hasselt, Belgium with additional offices in Houston, Texas and Köln, Germany. As of June 12, 2018, TrendMiner NV operates as a subsidiary of Software Aktiengesellschaft.
Rewind Therapeutics
Series A in 2018
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medical practitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
